ReP USP - Resultado da busca

Artigo de periodico
Cord blood transplantation for adult mature lymphoid neoplasms in Europe and Japan (2024)
Watanabe, Mizuki; Kanda, Junya; Volt, Fernanda; Ruggeri, Annalisa; Suzuki, Ritsuro; Rafii, Hanadi; Kimura, Fumihiko; Cappelli, Barbara; Kondo, Eisei; Rocha, Vanderson Geraldo
Source: Blood advances. Unidade: FM
Subjects: CÉLULAS-TRONCO, TRANSPLANTES, DOENÇAS LINFÁTICAS, EPIDEMIOLOGIA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
WATANABE, Mizuki et al. Cord blood transplantation for adult mature lymphoid neoplasms in Europe and Japan. Blood advances, v. 8, n. 3, p. 640-652, 2024Tradução . . Disponível em: https://observatorio.fm.usp.br/handle/OPI/58773. Acesso em: 01 nov. 2024.
APA
Watanabe, M., Kanda, J., Volt, F., Ruggeri, A., Suzuki, R., Rafii, H., et al. (2024). Cord blood transplantation for adult mature lymphoid neoplasms in Europe and Japan. Blood advances, 8( 3), 640-652. doi:10.1182/bloodadvances.2023010598
NLM
Watanabe M, Kanda J, Volt F, Ruggeri A, Suzuki R, Rafii H, Kimura F, Cappelli B, Kondo E, Rocha VG. Cord blood transplantation for adult mature lymphoid neoplasms in Europe and Japan [Internet]. Blood advances. 2024 ; 8( 3): 640-652.[citado 2024 nov. 01 ] Available from: https://observatorio.fm.usp.br/handle/OPI/58773
Vancouver
Watanabe M, Kanda J, Volt F, Ruggeri A, Suzuki R, Rafii H, Kimura F, Cappelli B, Kondo E, Rocha VG. Cord blood transplantation for adult mature lymphoid neoplasms in Europe and Japan [Internet]. Blood advances. 2024 ; 8( 3): 640-652.[citado 2024 nov. 01 ] Available from: https://observatorio.fm.usp.br/handle/OPI/58773
Artigo de periodico
Impact of allele-level HLA matching on outcomes after double cord blood transplantation in adults with malignancies (2023)
Fatobene, Giancarlo ; Compte, Lívia Caroline Mariano; Volt, Fernanda ; Moreira, Frederico Rafael; Conelissen, Jan; Furst, Sabine; Daguindau, Etienne; Sirvent, Anne; Latour, Régis Peffault de; Rafil, Hanadi
Source: Blood advances. Unidade: FM
Subjects: NEOPLASIAS, TRANSPLANTES, CÉLULAS-TRONCO, RESULTADO DE TRATAMENTO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
FATOBENE, Giancarlo et al. Impact of allele-level HLA matching on outcomes after double cord blood transplantation in adults with malignancies. Blood advances, v. 7, n. 13, p. 3297-3306, 2023Tradução . . Disponível em: https://observatorio.fm.usp.br/handle/OPI/55971. Acesso em: 01 nov. 2024.
APA
Fatobene, G., Compte, L. C. M., Volt, F., Moreira, F. R., Conelissen, J., Furst, S., et al. (2023). Impact of allele-level HLA matching on outcomes after double cord blood transplantation in adults with malignancies. Blood advances, 7( 13), 3297-3306. doi:10.1182/bloodadvances.2022009251
NLM
Fatobene G, Compte LCM, Volt F, Moreira FR, Conelissen J, Furst S, Daguindau E, Sirvent A, Latour RP de, Rafil H. Impact of allele-level HLA matching on outcomes after double cord blood transplantation in adults with malignancies [Internet]. Blood advances. 2023 ; 7( 13): 3297-3306.[citado 2024 nov. 01 ] Available from: https://observatorio.fm.usp.br/handle/OPI/55971
Vancouver
Fatobene G, Compte LCM, Volt F, Moreira FR, Conelissen J, Furst S, Daguindau E, Sirvent A, Latour RP de, Rafil H. Impact of allele-level HLA matching on outcomes after double cord blood transplantation in adults with malignancies [Internet]. Blood advances. 2023 ; 7( 13): 3297-3306.[citado 2024 nov. 01 ] Available from: https://observatorio.fm.usp.br/handle/OPI/55971
Artigo de periodico
Outcomes of subsequent neoplasms after umbilical cord blood transplantation in Europe (2023)
Rafii, Hanadi; Ruggeri, Annalisa; Kenzey, Chantal; Sanz, Jaime; Tour, Regis Peffault De la; Esquirol, Albert; Michel, Gerard; Chevallier, Patrice; Rubio, Marie-Therese; Rocha, Vanderson Geraldo
Source: Blood advances. Unidade: FM
Subjects: TRANSPLANTE AUTÓLOGO, CORDÃO UMBILICAL, DOENÇAS HEMATOLÓGICAS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
RAFII, Hanadi et al. Outcomes of subsequent neoplasms after umbilical cord blood transplantation in Europe. Blood advances, v. 7, n. 10, p. 1976-1986, 2023Tradução . . Disponível em: https://observatorio.fm.usp.br/handle/OPI/54596. Acesso em: 01 nov. 2024.
APA
Rafii, H., Ruggeri, A., Kenzey, C., Sanz, J., Tour, R. P. D. la, Esquirol, A., et al. (2023). Outcomes of subsequent neoplasms after umbilical cord blood transplantation in Europe. Blood advances, 7( 10), 1976-1986. doi:10.1182/bloodadvances.2022007941
NLM
Rafii H, Ruggeri A, Kenzey C, Sanz J, Tour RPD la, Esquirol A, Michel G, Chevallier P, Rubio M-T, Rocha VG. Outcomes of subsequent neoplasms after umbilical cord blood transplantation in Europe [Internet]. Blood advances. 2023 ; 7( 10): 1976-1986.[citado 2024 nov. 01 ] Available from: https://observatorio.fm.usp.br/handle/OPI/54596
Vancouver
Rafii H, Ruggeri A, Kenzey C, Sanz J, Tour RPD la, Esquirol A, Michel G, Chevallier P, Rubio M-T, Rocha VG. Outcomes of subsequent neoplasms after umbilical cord blood transplantation in Europe [Internet]. Blood advances. 2023 ; 7( 10): 1976-1986.[citado 2024 nov. 01 ] Available from: https://observatorio.fm.usp.br/handle/OPI/54596
Artigo de periodico
Use of letermovir in umbilical cord blood transplantation based on risk scores (2023)
Franco, Monica Magdalena Rivera ; Rafii, Hanadi ; Volt, Fernanda ; Kenzey, Chantal ; Cappelli, Barbara ; Scigliuolo, Graziana Maria; Rocha, Vanderson Geraldo ; Raus, Nicole; Dalle, Jean-Hugues; Chevallier, Patrice
Source: Blood advances. Unidade: FM
Subjects: TRANSPLANTES, CÉLULAS-TRONCO, ANTINEOPLÁSICOS, FATORES DE RISCO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
FRANCO, Monica Magdalena Rivera et al. Use of letermovir in umbilical cord blood transplantation based on risk scores. Blood advances, v. 7, n. 16, p. 4315-4318, 2023Tradução . . Disponível em: https://observatorio.fm.usp.br/handle/OPI/55963. Acesso em: 01 nov. 2024.
APA
Franco, M. M. R., Rafii, H., Volt, F., Kenzey, C., Cappelli, B., Scigliuolo, G. M., et al. (2023). Use of letermovir in umbilical cord blood transplantation based on risk scores. Blood advances, 7( 16), 4315-4318. doi:10.1182/bloodadvances.2023010573
NLM
Franco MMR, Rafii H, Volt F, Kenzey C, Cappelli B, Scigliuolo GM, Rocha VG, Raus N, Dalle J-H, Chevallier P. Use of letermovir in umbilical cord blood transplantation based on risk scores [Internet]. Blood advances. 2023 ; 7( 16): 4315-4318.[citado 2024 nov. 01 ] Available from: https://observatorio.fm.usp.br/handle/OPI/55963
Vancouver
Franco MMR, Rafii H, Volt F, Kenzey C, Cappelli B, Scigliuolo GM, Rocha VG, Raus N, Dalle J-H, Chevallier P. Use of letermovir in umbilical cord blood transplantation based on risk scores [Internet]. Blood advances. 2023 ; 7( 16): 4315-4318.[citado 2024 nov. 01 ] Available from: https://observatorio.fm.usp.br/handle/OPI/55963
Artigo de periodico
Somatic mutational landscape of hereditary hematopoietic malignancies caused by germline variants in RUNX1, GATA2, and DDX41 (2023)
Homan, Claire C; Drazer, Michael W; Yu, Kai; Lawrence, David M; Feng, Jinghua; Arriola-Martinez, Luis; Pozsgai, Matthew J; Mcneely, Kelsey E; Ha, Thuong; Velloso, Elvira Deolinda Rodrigues Pereira
Source: Blood advances. Unidade: FM
Subjects: DOENÇAS GENÉTICAS, LEUCÓCITOS, FATORES DE RISCO, MUTAÇÃO GENÉTICA, PREVALÊNCIA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
HOMAN, Claire C et al. Somatic mutational landscape of hereditary hematopoietic malignancies caused by germline variants in RUNX1, GATA2, and DDX41. Blood advances, v. 7, n. 20, p. 6092-6107, 2023Tradução . . Disponível em: https://observatorio.fm.usp.br/handle/OPI/57340. Acesso em: 01 nov. 2024.
APA
Homan, C. C., Drazer, M. W., Yu, K., Lawrence, D. M., Feng, J., Arriola-Martinez, L., et al. (2023). Somatic mutational landscape of hereditary hematopoietic malignancies caused by germline variants in RUNX1, GATA2, and DDX41. Blood advances, 7( 20), 6092-6107. doi:10.1182/bloodadvances.2023010045
NLM
Homan CC, Drazer MW, Yu K, Lawrence DM, Feng J, Arriola-Martinez L, Pozsgai MJ, Mcneely KE, Ha T, Velloso EDRP. Somatic mutational landscape of hereditary hematopoietic malignancies caused by germline variants in RUNX1, GATA2, and DDX41 [Internet]. Blood advances. 2023 ; 7( 20): 6092-6107.[citado 2024 nov. 01 ] Available from: https://observatorio.fm.usp.br/handle/OPI/57340
Vancouver
Homan CC, Drazer MW, Yu K, Lawrence DM, Feng J, Arriola-Martinez L, Pozsgai MJ, Mcneely KE, Ha T, Velloso EDRP. Somatic mutational landscape of hereditary hematopoietic malignancies caused by germline variants in RUNX1, GATA2, and DDX41 [Internet]. Blood advances. 2023 ; 7( 20): 6092-6107.[citado 2024 nov. 01 ] Available from: https://observatorio.fm.usp.br/handle/OPI/57340
Artigo de periodico
Targeted therapy with nanatinostat and valganciclovir in recurrent EBV-positive lymphoid malignancies: a phase 1b/2 study (2023)
Haverkos, Bradley; Alpdogan, Onder; Baiocchi, Robert; Brammer, Jonathan E; Feldman, Tatyana A; Capra, Marcelo; Brem, Elizabeth A; Nair, Santosh; Scheinberg, Phillip; Pereira, Juliana
Source: Blood advances. Unidade: FM
Subjects: LINFOMA, INFECÇÕES POR VÍRUS DE DNA, INIBIDORES DE ENZIMAS, APOPTOSE
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
HAVERKOS, Bradley et al. Targeted therapy with nanatinostat and valganciclovir in recurrent EBV-positive lymphoid malignancies: a phase 1b/2 study. Blood advances, v. 7, n. 20, p. 6339-6350, 2023Tradução . . Disponível em: https://observatorio.fm.usp.br/handle/OPI/57344. Acesso em: 01 nov. 2024.
APA
Haverkos, B., Alpdogan, O., Baiocchi, R., Brammer, J. E., Feldman, T. A., Capra, M., et al. (2023). Targeted therapy with nanatinostat and valganciclovir in recurrent EBV-positive lymphoid malignancies: a phase 1b/2 study. Blood advances, 7( 20), 6339-6350. doi:10.1182/bloodadvances.2023010330
NLM
Haverkos B, Alpdogan O, Baiocchi R, Brammer JE, Feldman TA, Capra M, Brem EA, Nair S, Scheinberg P, Pereira J. Targeted therapy with nanatinostat and valganciclovir in recurrent EBV-positive lymphoid malignancies: a phase 1b/2 study [Internet]. Blood advances. 2023 ; 7( 20): 6339-6350.[citado 2024 nov. 01 ] Available from: https://observatorio.fm.usp.br/handle/OPI/57344
Vancouver
Haverkos B, Alpdogan O, Baiocchi R, Brammer JE, Feldman TA, Capra M, Brem EA, Nair S, Scheinberg P, Pereira J. Targeted therapy with nanatinostat and valganciclovir in recurrent EBV-positive lymphoid malignancies: a phase 1b/2 study [Internet]. Blood advances. 2023 ; 7( 20): 6339-6350.[citado 2024 nov. 01 ] Available from: https://observatorio.fm.usp.br/handle/OPI/57344
Artigo de periodico-carta/editorial
Clonal hematopoiesis in patients with ANKRD26 or ETV6 germline mutations. [Carta] (2022)
Drazer, Michael W; Homan, Claire C; Yu, Kai; Silva, Marcela Cavalcante de Andrade; Mcneely, Kelsey E; Pozsgai, Matthew J; Acevedo-Mendez, Maria G; Segal, Jeremy P; Wang, Peng; Velloso, Elvira Deolinda Rodrigues Pereira
Source: Blood advances. Unidade: FM
Subjects: HEMATOPOESE, PREDISPOSIÇÃO GENÉTICA PARA DOENÇA, MUTAÇÃO, PEPTÍDEOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
DRAZER, Michael W et al. Clonal hematopoiesis in patients with ANKRD26 or ETV6 germline mutations. [Carta]. Blood advances. Amsterdam: Faculdade de Medicina, Universidade de São Paulo. Disponível em: https://doi.org/10.1182/bloodadvances.2022007211. Acesso em: 01 nov. 2024. , 2022
APA
Drazer, M. W., Homan, C. C., Yu, K., Silva, M. C. de A., Mcneely, K. E., Pozsgai, M. J., et al. (2022). Clonal hematopoiesis in patients with ANKRD26 or ETV6 germline mutations. [Carta]. Blood advances. Amsterdam: Faculdade de Medicina, Universidade de São Paulo. doi:10.1182/bloodadvances.2022007211
NLM
Drazer MW, Homan CC, Yu K, Silva MC de A, Mcneely KE, Pozsgai MJ, Acevedo-Mendez MG, Segal JP, Wang P, Velloso EDRP. Clonal hematopoiesis in patients with ANKRD26 or ETV6 germline mutations. [Carta] [Internet]. Blood advances. 2022 ; 6( 15): 4357-4359.[citado 2024 nov. 01 ] Available from: https://doi.org/10.1182/bloodadvances.2022007211
Vancouver
Drazer MW, Homan CC, Yu K, Silva MC de A, Mcneely KE, Pozsgai MJ, Acevedo-Mendez MG, Segal JP, Wang P, Velloso EDRP. Clonal hematopoiesis in patients with ANKRD26 or ETV6 germline mutations. [Carta] [Internet]. Blood advances. 2022 ; 6( 15): 4357-4359.[citado 2024 nov. 01 ] Available from: https://doi.org/10.1182/bloodadvances.2022007211
Artigo de periodico
Integrating clinical features with genetic factors enhances survival prediction for adults with acute myeloid leukemia (2020)
Silveira, Douglas R. A; Quek, Lynn; Santos, Itamar de Souza ; Corby, Anna; Coelho-silva, Juan L; Martins, Diego Antonio Pereira ; Vallance, Grant; Velloso, Elvira Deolinda Rodrigues Pereira ; Traina, Fabiola ; Rego, Eduardo Magalhaes ; Rocha, Vanderson Geraldo
Source: Blood advances. Unidades: FM, FMRP
Subjects: LEUCEMIA MIELOIDE AGUDA, TERAPÊUTICA, DIAGNOSE FOLIAR, CONTAGEM DE LEUCÓCITOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
SILVEIRA, Douglas R. A et al. Integrating clinical features with genetic factors enhances survival prediction for adults with acute myeloid leukemia. Blood advances, v. 4, n. 10, p. 2339-2350, 2020Tradução . . Disponível em: https://doi.org/10.1182/bloodadvances.2019001419. Acesso em: 01 nov. 2024.
APA
Silveira, D. R. A., Quek, L., Santos, I. de S., Corby, A., Coelho-silva, J. L., Martins, D. A. P., et al. (2020). Integrating clinical features with genetic factors enhances survival prediction for adults with acute myeloid leukemia. Blood advances, 4( 10), 2339-2350. doi:10.1182/bloodadvances.2019001419
NLM
Silveira DRA, Quek L, Santos I de S, Corby A, Coelho-silva JL, Martins DAP, Vallance G, Velloso EDRP, Traina F, Rego EM, Rocha VG. Integrating clinical features with genetic factors enhances survival prediction for adults with acute myeloid leukemia [Internet]. Blood advances. 2020 ; 4( 10): 2339-2350.[citado 2024 nov. 01 ] Available from: https://doi.org/10.1182/bloodadvances.2019001419
Vancouver
Silveira DRA, Quek L, Santos I de S, Corby A, Coelho-silva JL, Martins DAP, Vallance G, Velloso EDRP, Traina F, Rego EM, Rocha VG. Integrating clinical features with genetic factors enhances survival prediction for adults with acute myeloid leukemia [Internet]. Blood advances. 2020 ; 4( 10): 2339-2350.[citado 2024 nov. 01 ] Available from: https://doi.org/10.1182/bloodadvances.2019001419
Artigo de periodico
Myeloablative vs reduced intensity T-cell-replete haploidentical transplantation for hematologic malignancy (2019)
Solomon, Scott R; Martin, Andrew St; Shah, Nirav N; Fatobene, Giancarlo; Malki, Monzr M. Al; Ballen, Karen K; Bashey, Asad; Bejanyan, Nelli; Meade, Javier Bolanos; Rocha, Vanderson
Source: Blood advances. Unidade: FM
Subjects: TRANSPLANTE HOMÓLOGO, LINFÓCITOS T, LEUCEMIA MIELOIDE AGUDA, DOENÇAS DA MEDULA ÓSSEA, DOENÇA ENXERTO-HOSPEDEIRO, FÁRMACOS IMUNOSSUPRESSORES, CONDICIONAMENTO, SOBREVIVÊNCIA LIVRE DE DOENÇA, ESTUDOS RETROSPECTIVOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
SOLOMON, Scott R et al. Myeloablative vs reduced intensity T-cell-replete haploidentical transplantation for hematologic malignancy. Blood advances, v. 3, n. 19, p. 2836-2844, 2019Tradução . . Disponível em: https://doi.org/10.1182/bloodadvances.2019000627. Acesso em: 01 nov. 2024.
APA
Solomon, S. R., Martin, A. S., Shah, N. N., Fatobene, G., Malki, M. M. A., Ballen, K. K., et al. (2019). Myeloablative vs reduced intensity T-cell-replete haploidentical transplantation for hematologic malignancy. Blood advances, 3( 19), 2836-2844. doi:10.1182/bloodadvances.2019000627
NLM
Solomon SR, Martin AS, Shah NN, Fatobene G, Malki MMA, Ballen KK, Bashey A, Bejanyan N, Meade JB, Rocha V. Myeloablative vs reduced intensity T-cell-replete haploidentical transplantation for hematologic malignancy [Internet]. Blood advances. 2019 ; 3( 19): 2836-2844.[citado 2024 nov. 01 ] Available from: https://doi.org/10.1182/bloodadvances.2019000627
Vancouver
Solomon SR, Martin AS, Shah NN, Fatobene G, Malki MMA, Ballen KK, Bashey A, Bejanyan N, Meade JB, Rocha V. Myeloablative vs reduced intensity T-cell-replete haploidentical transplantation for hematologic malignancy [Internet]. Blood advances. 2019 ; 3( 19): 2836-2844.[citado 2024 nov. 01 ] Available from: https://doi.org/10.1182/bloodadvances.2019000627
Artigo de periodico
The application of an integrated clinical, cytogenetic, and molecular risk stratification for acute myeloid leukemia patients using a central laboratory in a Brazilian multicentric study (2017)
Silva, Fernanda Borges da; Figueiredo-Pontes, Lorena Lobo de; Madeira, Maria Isabel Ayrosa; Koury, Luisa Corrêa de Araujo; Lima, Ana Silvia Gouvêa de; Scheucher, Priscila Santos; Coelho-Silva, Juan Luiz; Velloso, Elvira Deolinda Rodrigues Pereira; Rego, Eduardo Magalhães; Traina, Fabiola
Source: Blood advances. Unidades: FM, FMRP
Subjects: LEUCEMIA MIELOIDE, CITOGENÉTICA, BRASILEIROS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
SILVA, Fernanda Borges da et al. The application of an integrated clinical, cytogenetic, and molecular risk stratification for acute myeloid leukemia patients using a central laboratory in a Brazilian multicentric study. Blood advances, v. 1, p. 86-89, 2017Tradução . . Disponível em: https://doi.org/10.1182/bloodadvances.2017GS102419. Acesso em: 01 nov. 2024.
APA
Silva, F. B. da, Figueiredo-Pontes, L. L. de, Madeira, M. I. A., Koury, L. C. de A., Lima, A. S. G. de, Scheucher, P. S., et al. (2017). The application of an integrated clinical, cytogenetic, and molecular risk stratification for acute myeloid leukemia patients using a central laboratory in a Brazilian multicentric study. Blood advances, 1, 86-89. doi:10.1182/bloodadvances.2017GS102419
NLM
Silva FB da, Figueiredo-Pontes LL de, Madeira MIA, Koury LC de A, Lima ASG de, Scheucher PS, Coelho-Silva JL, Velloso EDRP, Rego EM, Traina F. The application of an integrated clinical, cytogenetic, and molecular risk stratification for acute myeloid leukemia patients using a central laboratory in a Brazilian multicentric study [Internet]. Blood advances. 2017 ; 1 86-89.[citado 2024 nov. 01 ] Available from: https://doi.org/10.1182/bloodadvances.2017GS102419
Vancouver
Silva FB da, Figueiredo-Pontes LL de, Madeira MIA, Koury LC de A, Lima ASG de, Scheucher PS, Coelho-Silva JL, Velloso EDRP, Rego EM, Traina F. The application of an integrated clinical, cytogenetic, and molecular risk stratification for acute myeloid leukemia patients using a central laboratory in a Brazilian multicentric study [Internet]. Blood advances. 2017 ; 1 86-89.[citado 2024 nov. 01 ] Available from: https://doi.org/10.1182/bloodadvances.2017GS102419

USP Schools

ReP

Filtros

Authors

USP affiliated authors

Date published

Subjects

Funding Agencies

Non normalized affiliation